Clay B. Siegall, Ph.D.

President, Chief Executive Officer and Chairman of the Board

In 1998, Clay co-founded Seattle Genetics. It was a time when cancer treatments were dominated by chemotherapies that didn’t differentiate between killing cancer cells and normal cells. His vision was to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs.

A scientist by training, Clay built Seattle Genetics on a foundation of scientific innovation, rigorous research and drug development practices as well as a passion for helping patients. He has guided the company to its current leadership position in the field of antibody-drug conjugates (ADCs) and in the 2011 FDA approval of our first ADC product, ADCETRIS® (brentuximab vedotin). Under a collaboration with Takeda Pharmaceutical Company, ADCETRIS is now a global brand that is approved in 70 countries. Seattle Genetics is also advancing a diverse pipeline of proprietary ADCs for the treatment of cancer.

Under Clay’s leadership, Seattle Genetics has entered in to multiple strategic licenses for our ADC technology, including with Astellas, Genentech (Roche), AbbVie, and GlaxoSmithKline, that have generated more than $400 million to date. Clay has also led Seattle Genetics’ capital-raising activities, securing more than $1.8 billion through public and private financings, including the company’s initial public offering in 2001.

Year joined:

1998 as co-founder


Bristol-Myers Squibb Pharmaceutical Research Institute

National Institutes of Health, National Cancer Institute


2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences

2012 Pacific Northwest Ernst & Young Entrepreneur of the Year


Author on more than 70 publications

Holds 15 patents


Ph.D., Genetics, George Washington University

B.S., Zoology, University of Maryland


Director, Ultragenyx Pharmaceutical

Director, Alder BioPharmaceuticals

Director, Washington Roundtable

Roger D. Dansey, M.D.

Chief Medical Officer

Roger joined Seattle Genetics as Chief Medical Officer in May 2018, bringing extensive experience in cancer drug development. His most recent experience was with Merck Inc. where he was Therapeutic Area Head for Late Stage Oncology, responsible for the ongoing registration efforts for KEYTRUDA® (pembrolizumab) across multiple tumor types. His deep oncology background and proven leadership will help drive our transition to a global, multi-product oncology company.

Year joined:



Senior Vice President, Merck Inc.
Led late-stage oncology development efforts, including the approved PD-1 inhibitor, KEYTRUDA®

Vice President, Oncology Clinical Research, Gilead Sciences

Various roles of increasing responsibility, Amgen
Oncology and hematology therapeutic areas, including Global Development Leader for XGEVA®


M.D., University of Witwatersrand, Johannesburg, South Africa

Vaughn B. Himes, Ph.D.

Chief Technical Officer

Vaughn has 25+ years of product development and commercialization experience in large pharmaceutical and biotechnology companies, with expertise in quality, manufacturing, technical operations, process development and scale-up activities. He leads the Seattle Genetics manufacturing, supply chain, process sciences and quality functions supporting our successful commercialization of ADCETRIS and a robust pipeline of product candidates. 

Year joined:


Other positions held:

Executive Vice President, Process Sciences and Technical Operations


Senior Vice President, Technical Operations - ZymoGenetics
Commercial and clinical manufacturing, supply chain and logistics, quality control and process development; responsible for CMC portion of successful BLA for Recothrom and commercial supply

Vice President, Worldwide Manufacturing Operations – Corixa
Commercial products include Bexxar and MPL

Experience cont.:

Vice President, Manufacturing Operations - Targeted Genetics
Manufacturing operations for clinical supply of gene delivery products

Vice President, Product Development - Genovo

Associate Director, Biological Development - Wyeth-Lederle Vaccines


Ph.D, Chemical Engineering, University of Minnesota

B.A., Chemistry, Pomona College

Todd E. Simpson

Chief Financial Officer

Todd brought his extensive industry experience in senior financial positions with public biotechnology companies to his role as our CFO. He’s leveraged that experience to grow our Finance and Facilities groups to accommodate the company’s continuing growth. Our campus and finance systems are well-positioned for fulfilling our mission.

Year joined:



Vice President, Finance and Administration and Chief Financial Officer, Targeted Genetics, 2001-2005

Vice President, Finance and Administration and Chief Financial Officer, Aastrom Biosciences, 1996-2001

Integra Life Sciences Corporation

Telios Pharmaceuticals, Inc. (acquired by Integra in 1995)

Ernst & Young LLP, 1983-1992 with a focus in life sciences and technology practices


Certified Public Accountant

B.S., Accounting and Computer Science, Oregon State University


Director, Aquinox Pharmaceuticals

Robin G. Taylor, M.B.A., Ph.D.

Chief Commercial Officer

Robin joined Seattle Genetics as the company’s first Chief Commercial Officer in May 2019. He brings 18 years of biotechnology and pharmaceutical company experience in the commercialization of oncology drugs, including significant marketing, launch and global product strategy roles at both Genentech/Roche and AstraZeneca. He contributed to several leading global brands, including TECENTRIQ® (atezolizumab), ALECENSA® (alectinib), AVASTIN® (bevacizumab) and HERCEPTIN® (trastuzumab).

Year joined:



Vice President, Immuno-Oncology Franchise Head, Oncology Business Unit, AstraZeneca
Led global marketing and product teams for IMFINZI® (durvalumab)

Vice President, Cancer Immunotherapy Franchise Head, Global Product Strategy, Genentech, a Member of the Roche Group
Responsible for the global development and launch of TECENTRIQ

Served in roles of increasing responsibility at Genentech, a Member of the Roche Group 2001-2018


Ph.D., Molecular and Medical Genetics, University of Toronto

M.B.A., University of California Berkeley

B.S., University of British Columbia

Jean I. Liu, J.D.

General Counsel, Executive VP, Legal Affairs

Jean oversees all aspects of the company’s legal, compliance and intellectual property functions and serves as Corporate Secretary. Her experience allows her to partner with management on the highest level of corporate strategic matters.

Year joined:



Vice President and General Counsel, Halozyme

Chief Legal Officer and Corporate Secretary and other roles, Durect Corporation

Pillsbury, Madison & Sutro (now Pillsbury Winthrop), Venture Law Group
Legal advising for early stage companies, including technology transfer, licensing, patents and copyright and trademark litigation


J.D, Columbia University

Harlan Fiske Stone Scholar

M.S., Biology, Stanford University

B.S., Cellular and Molecular Biology with highest distinction, University of Michigan

Christopher Pawlowicz

Executive VP, Human Resources

Chris has more than 30 years of human resources experience, principally in the pharmaceutical industry.

Year joined:


Other positions held:

Senior Vice President, Human Resources


Senior Vice President, Human Resources and Administration, MedPointe Pharmaceuticals
Part of the turnaround team that successfully restructured and sold the business to Meda Pharmaceuticals

Experience cont.:

Corporate Vice President, Human Resources, Express Scripts
The nation’s third largest pharmacy benefit management company

Senior human resources positions at Pharmacia, Searle and Monsanto
Global launch of Celebrex, the start-up of biotechnology teams in plant sciences, support of high growth commercial investments in Latin America, Europe and Asia, and post-merger integration of numerous companies


M.A., Labor and Industrial Relations, University of Illinois at Urbana-Champaign

B.A., Economics, Benedictine College, summa cum laude

Rachel Lenington

Senior VP, Program and Portfolio Management

Rachel brings over 20 years of diverse leadership and management experience from a variety of sectors including global public health and biotech to her leadership of our portfolio strategy, partnerships and global product development efforts.  She leverages this experience to advance and deliver on corporate, portfolio and product strategies and support Seattle Genetics’ transition to a global, multi-product oncology company.

Year joined:


Other positions held:

Vice President, Program, Portfolio and Alliance Management

Global Product Leader, ADCETRIS


Bill & Melinda Gates Foundation, responsible for the strategy and business operations of the Malaria and Neglected Infectious Diseases programs and leading alliances with product development organizations and country Ministries of Health

Experience cont.:

Amgen, drove the successful global development and commercialization strategy for Prolia® (denosumab)

Accenture and Deloitte Consulting, management consulting for clients such as Microsoft, Hewlett-Packard, Immunex, Sprint and Starbucks


M.B.A., Pepperdine University

B.A., Business, University of Washington

Natasha Hernday

Senior VP, Corporate Development

Natasha has broad experience in business and corporate development including in-licensing, out-licensing, venture capital and mergers and acquisitions. Since joining Seattle Genetics, she has successfully executed numerous technology licensing and platform deals with major pharma partners. She was instrumental in the acquisitions of our manufacturing facility, as well as bringing tucatinib and tisotumab vedotin into our pipeline.

Year joined:


Other positions held:

Vice President, Business Development


- Senior member of mergers and acquisitions team in corporate development
- Lead for out-licensing efforts
- Roles in research, research project management and business development finance


M.B.A., Pepperdine University

B.A., Biology, University of California Santa Barbara

Director, PDL BioPharma, Inc.

Member, External Advisory Board for the University of Oregon’s Knight Campus for Accelerating Scientific Impact